Comparative Pharmacology
Head-to-head clinical analysis: LUNELLE versus SEASONIQUE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LUNELLE versus SEASONIQUE.
LUNELLE vs SEASONIQUE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lunelle is a combination contraceptive injection containing medroxyprogesterone acetate and estradiol cypionate. It suppresses gonadotropin secretion, inhibiting ovulation and thickening cervical mucus to prevent sperm penetration.
Combination of ethinyl estradiol (estrogen) and levonorgestrel (progestin) that inhibits ovulation by suppressing gonadotropin-releasing hormone (GnRH), follicle-stimulating hormone (FSH), and luteinizing hormone (LH); increases cervical mucus viscosity and alters endometrial receptivity.
150 mg intramuscular injection on day 5 of menstrual cycle, then every 90 days thereafter.
One tablet daily orally: 84 days of ethinyl estradiol 0.02 mg / levonorgestrel 0.1 mg (active), followed by 7 days of ethinyl estradiol 0.01 mg.
None Documented
None Documented
Terminal elimination half-life of 20-30 hours in healthy adults; prolonged to 40-60 hours in moderate renal impairment (CrCl 30-50 mL/min). Clinically, steady state reached in 4-5 days.
Ethinyl estradiol: approximately 15.9 hours (range 9-28 hours); Levonorgestrel: approximately 24.4 hours (range 12-48 hours). Terminal elimination half-life accounts for steady-state attainment within 5-7 days.
Primarily renal (~70% as unchanged drug and inactive metabolites), with ~20% biliary/fecal elimination. Minimal dose recovered in feces as parent compound.
Renal: approximately 60% (as glucuronide and sulfate conjugates); Fecal: approximately 40% (as metabolites, with enterohepatic recycling).
Category C
Category C
Contraceptive
Contraceptive, Combination Hormonal